QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Résumé Extracto Full Text PDF For Our Patients Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Articles Ahead of Print [Order Reprint] Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jones, S C. Search for Related Content PubMed PubMed Citation Articles by Jones, S C.

ADVERSE DRUG REACTIONS

Relative Thromboembolic Risks Associated with COX-2 Inhibitors

Graduate Student, Department of Public Health Sciences, University of Virginia, Charlottesville, VA

Reprints: Dr. Jones, 3504 Arabian Place, Suffolk, VA 23435-3243, schrisjones{at}yahoo.com

OBJECTIVE: To evaluate the clinical literature on cyclooxygenase-2 (COX-2) inhibitors to determine whether a greater incidence of thromboembolic events is universal within the drug class.

DATA SOURCES: A MEDLINE search was conducted (1996–March 2005) for key articles in the English language assessing the efficacy or safety of these agents.

STUDY SELECTION AND DATA EXTRACTION: Randomized, double-blind, and controlled trials, as well as case–control and retrospective cohort studies, that assessed the cardiovascular safety of COX-2 inhibitors were reviewed.

DATA SYNTHESIS: Seventeen published studies were reviewed, and the cardiovascular safety data were extracted from each trial.

The mechanism by which COX-2 inhibitors may induce a thromboembolic event is likely multifactorial involving (1) COX-2–specific isoform binding affinity, (2) drug dose, (3) duration of therapy, and (4) cardiovascular risk profile of the patient. Evidence supports an association between cardiovascular adverse events and the use of rofecoxib, valdecoxib, and celecoxib. However, this risk is not equally distributed among the drugs. Given the relative paucity of data, lumiracoxib and etoricoxib cardiovascular effects remain uncertain.

CONCLUSIONS: Each COX-2 inhibitor has a unique cardiovascular risk profile. Based on the current evidence, celecoxib is the safest COX-2 inhibitor when prescribed appropriately in the lowest possible dose for the shortest duration in the ideal target population.

Key Words: cyclooxygenase-2 inhibitors: celecoxib, etoricoxib, lumiracoxib, parecoxib, rofecoxib, thromboembolism, valdecoxib

Published Online, June 14, 2005. www.theannals.com, DOI 10.1345/aph.1E654

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-05-020-H01

This article has been cited by other articles:

				F. Dentali, J. D Douketis, K. Woods, L. Thabane, G. Foster, A. Holbrook, and M. Crowther Does Celecoxib Potentiate the Anticoagulant Effect of Warfarin? A Randomized, Double-Blind, Controlled Trial Ann. Pharmacother., July 1, 2006; 40(7): 1241 - 1247. [Abstract] [Full Text] [PDF]

				F. Andersohn, S. Suissa, and E. Garbe Use of First- and Second-Generation Cyclooxygenase-2-Selective Nonsteroidal Antiinflammatory Drugs and Risk of Acute Myocardial Infarction Circulation, April 25, 2006; 113(16): 1950 - 1957. [Abstract] [Full Text] [PDF]

				B. Rocca Targeting PGE2 Receptor Subtypes Rather Than Cyclooxygenases: A Bridge Over Troubled Water? Mol. Interv., April 1, 2006; 6(2): 68 - 73. [Abstract] [Full Text] [PDF]

				J. A. Zonder Thrombotic Complications of Myeloma Therapy Hematology, January 1, 2006; 2006(1): 348 - 355. [Abstract] [Full Text] [PDF]